Praziquantel treatment coverage among school age children against Schistosomiasis and associated factors in Ethiopia: a cross-sectional survey, 2019.
Adolescent
Age Factors
Animals
Anthelmintics
/ therapeutic use
Child
Cross-Sectional Studies
Deglutition
Delivery of Health Care
/ methods
Ethiopia
/ epidemiology
Female
Humans
Male
Patient Compliance
Praziquantel
/ therapeutic use
Prevalence
Public Health
Schistosoma mansoni
Schistosomiasis mansoni
/ drug therapy
Sex Factors
Students
Surveys and Questionnaires
Coverage validation survey
Ethiopia
Mass drug administration
PZQ
Preventive chemotherapy
SAC
SCH
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
23 Nov 2020
23 Nov 2020
Historique:
received:
12
03
2020
accepted:
16
10
2020
entrez:
23
11
2020
pubmed:
24
11
2020
medline:
15
12
2020
Statut:
epublish
Résumé
World Health Organization estimated that 779 million people are at risk of getting schistosomiasis (SCH) and 240 million people were infected worldwide. SCH due to Schistosoma mansoni (S. mansoni) is a wide public health problem in Ethiopia. The aim of the survey was to quantify national and district disaggregated treatment coverage status for SCH and compare validated coverage with the one reported. Community based cross-sectional survey was conducted in April 2019 among households with school age children (SAC) 5-14 years in seven purposively selected districts of the country. Segments to be surveyed were randomly selected and households to be interviewed from each segment were determined using systematic sampling technique. A total of 3378 households visited and 5679 SAC (5-14 years) were interviewed. Overall reported treatment coverage of Praziquantel (PZQ) against SCH was 4286 (75.5%). Males were 27% more likely to swallow the drug (AOR = 1.27; 95% CI: 1.09, 1.47) than females. SAC with age 10-14 years were 45% more likely to swallow the drug compared with their counter parts (5-9 years), (AOR =1.45; 95% CI: 1.25, 1.69). There is statistically significant association between PZQ swallowing status with school enrollment. (AOR = 20.90, 95% CI: 17.41, 25.08). Swallowing status of PZQ against SCH significantly higher for SAC treated in districts applied integrated treatment approach (87.5%) compared with SAC treated in vertical treatment approach (72.5%); P-value < 0.001. SACs were asked for reasons for not taking the drug and the main reported reason for not swallowing PZQ in the present study was none attending of the school. Over all treatment coverage of PZQ against SCH in the present study was 75.5%. Although it is in accordance with WHO recommendation for Ethiopia, national programmatic improvements are necessary to achieve higher coverage in the future. To increase treatment coverage for PZQ against SCH in Ethiopia, school based training should target all schools. Moreover, mobilization, sensitization and implementation of the community wide treatment need to be improved.
Sections du résumé
BACKGROUND
BACKGROUND
World Health Organization estimated that 779 million people are at risk of getting schistosomiasis (SCH) and 240 million people were infected worldwide. SCH due to Schistosoma mansoni (S. mansoni) is a wide public health problem in Ethiopia. The aim of the survey was to quantify national and district disaggregated treatment coverage status for SCH and compare validated coverage with the one reported.
METHODS
METHODS
Community based cross-sectional survey was conducted in April 2019 among households with school age children (SAC) 5-14 years in seven purposively selected districts of the country. Segments to be surveyed were randomly selected and households to be interviewed from each segment were determined using systematic sampling technique. A total of 3378 households visited and 5679 SAC (5-14 years) were interviewed.
RESULTS
RESULTS
Overall reported treatment coverage of Praziquantel (PZQ) against SCH was 4286 (75.5%). Males were 27% more likely to swallow the drug (AOR = 1.27; 95% CI: 1.09, 1.47) than females. SAC with age 10-14 years were 45% more likely to swallow the drug compared with their counter parts (5-9 years), (AOR =1.45; 95% CI: 1.25, 1.69). There is statistically significant association between PZQ swallowing status with school enrollment. (AOR = 20.90, 95% CI: 17.41, 25.08). Swallowing status of PZQ against SCH significantly higher for SAC treated in districts applied integrated treatment approach (87.5%) compared with SAC treated in vertical treatment approach (72.5%); P-value < 0.001. SACs were asked for reasons for not taking the drug and the main reported reason for not swallowing PZQ in the present study was none attending of the school.
CONCLUSIONS
CONCLUSIONS
Over all treatment coverage of PZQ against SCH in the present study was 75.5%. Although it is in accordance with WHO recommendation for Ethiopia, national programmatic improvements are necessary to achieve higher coverage in the future. To increase treatment coverage for PZQ against SCH in Ethiopia, school based training should target all schools. Moreover, mobilization, sensitization and implementation of the community wide treatment need to be improved.
Identifiants
pubmed: 33225918
doi: 10.1186/s12879-020-05519-0
pii: 10.1186/s12879-020-05519-0
pmc: PMC7682081
doi:
Substances chimiques
Anthelmintics
0
Praziquantel
6490C9U457
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
872Références
Parasit Vectors. 2015 Jul 16;8:377
pubmed: 26178484
BMC Public Health. 2016 May 23;16:422
pubmed: 27216255
PLoS One. 2016 May 20;11(5):e0155915
pubmed: 27203749
BMC Infect Dis. 2011 Jul 09;11:189
pubmed: 21740589
Trop Med Infect Dis. 2018 Jun 19;3(2):
pubmed: 30274465
Parasit Vectors. 2016 Jan 04;9:5
pubmed: 26727915
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):338-42
pubmed: 8990210
Infect Dis Poverty. 2013 Jun 10;2(1):11
pubmed: 23849481
Parasit Vectors. 2014 Jan 09;7:15
pubmed: 24406075
Infect Dis Poverty. 2019 Jan 10;8(1):1
pubmed: 30626428
Acta Trop. 2000 Oct 23;77(1):41-51
pubmed: 10996119
Expert Opin Pharmacother. 2004 Feb;5(2):263-85
pubmed: 14996624
J R Soc Interface. 2009 Jun 6;6(35):495-508
pubmed: 18782722
Trans R Soc Trop Med Hyg. 1999 Sep-Oct;93(5):497-502
pubmed: 10696404
J Parasitol Res. 2014;2014:792536
pubmed: 24800058